El capital riesgo inyecta 150 millones de euros en empresas biomédicas
En resumen
Las 'start up' del sector de las ciencias de la vida captan un 30% menos en operaciones de financiación en el primer semestre, en comparación con un 2025 marcado por la megarronda de SpliceBio. Leer
- Fuente primaria
- Portada // expansion — Leer artículo original
- Publicado
- Tema
- Finanzas
Las 'start up' del sector de las ciencias de la vida captan un 30% menos en operaciones de financiación en el primer semestre, en comparación con un 2025 marcado por la megarronda de SpliceBio. Leer
Este resumen proviene de Portada // expansion. Lee el artículo completo en la fuente original.
Referencias
Más en Tecnología
Nvidia lines up $500 billion in financing as CEO Jensen Huang tells CNBC his chips are ‘investable asset’
Nvidia CEO Jensen Huang argued that because its hardware is broadly adopted, flexible and transferable, lenders can underwrite compute as revenue-generating.
Rocket Lab reveals some big plans, but its stock is dropping on mixed earnings
The company is looking to expand its reach in Europe and building up its backlog.
Wall Street thinks inflation is under control. Here’s why investors shouldn’t buy it.
Uncle Sam needs inflation, not just economic growth, to escape today’s debt crisis.
I looked into buying a house in Singapore as an investment. Here’s why I didn’t — despite the 2% mortgage rate.
Home-loan interest rates in Singapore are less than 2%, while in Japan they’re around 1% or even lower. That’s in stark contrast to mortgage rates in America and Australia, which…